Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 2/20 | 1.00 |
| ▸ | PTPN6 | P29350 | 2/20 | 1.00 |
| ▸ | HNF4A | P41235 | 1/20 | 0.89 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.79 |
| ▸ | LCK | P06239 | 1/20 | 0.72 |
| ▸ | APP | P05067 | 5/20 | 0.70 |
| ▸ | DHODH | Q02127 | 1/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29938670 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL6266629 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL6266631 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL30075246 | 0.94 | PTPN1 (1.00) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL7711868 | 0.94 | PTPN1 (0.89) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL673426 | 0.94 | PTPN1 (1.00) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL1603423 | 0.94 | PTPN1 (0.89) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL1603420 | 0.94 | PTPN1 (0.89) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL21385358 | 0.94 | PTPN1 (1.00) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL23143169 | 0.91 | PTPN1 (0.83) | PTPN1PTPN2PTPN6HNF4APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4323773-A1 | METHODS AND MATERIALS FOR DETECTING MISFOLDED POLYPEPTIDES | Regents of the University of Minnesota (US) | 2024-02-21 | — | — | EP | claimed |
| WO-2022221683-A1 | METHODS AND MATERIALS FOR DETECTING MISFOLDED POLYPEPTIDES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-10-20 | — | — | WO | claimed |
| WO-2020242246-A1 | AMYLOID-BETA OLIGOMER DETECTION METHOD | 주식회사 캔티스 | 2020-12-03 | — | — | WO | claimed |
| US-20070224593-A1 | Diagnosis of transmissible spongiform encephalopathy | GOLDSTEIN LEE E | 2007-09-27 | — | — | US | claimed |
| US-20050227941-A1 | Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-13 | — | — | US | claimed |
| US-20250231165-A1 | DRUG PRODUCT SURROGATE SOLUTIONS | MODERNATX, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2023069625-A1 | DRUG PRODUCT SURROGATE SOLUTIONS | MODERNATX, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11125758-B2 | Methods and kits for detecting misfolded proteins | YALE UNIVERSITY (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210255192-A1 | METHODS AND KITS FOR DETECTING MISFOLDED PROTEINS | YALE UNIVERSITY (US) | 2021-08-19 | — | — | US | disclosed |
| WO-2020242246-A1 | AMYLOID-BETA OLIGOMER DETECTION METHOD | 주식회사 캔티스 | 2020-12-03 | — | — | WO | disclosed |
| CN-110208540-A | The method and composition of preeclampsia detection and treatment | 耶鲁大学 | 2019-09-06 | — | — | CN | disclosed |
| CN-110187121-A | The method and composition of preeclampsia detection and treatment | 耶鲁大学 | 2019-08-30 | — | — | CN | disclosed |
| US-20030138374-A1 | Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same | BF RESEARCH INSTITUTE, INC. (JP) | 2003-07-24 | — | — | US | disclosed |
| EP-1266884-A1 | IMAGE DIAGNOSIS PROBE BASED ON SUBSTITUTED AZOBENZENE OR ANALOGUE THEREOF FOR DISEASE ATTRIBUTABLE TO AMYLOID ACCUMULATION AND COMPOSITION FOR IMAGE DIAGNOSIS CONTAINING THE SAME | BF Research Institute, Inc. (JP) | 2002-12-18 | — | — | EP | disclosed |
| US-6417178-B1 | Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits | UNIVERSITY OF PITTSBURGH | 2002-07-09 | — | — | US | disclosed |
| US-6168776-B1 | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | UNIVERSITY OF PITTSBURGH | 2001-01-02 | — | — | US | disclosed |
| US-6133259-A | DIAGNOSIS OF ALZHEIMER'S DISEASE | UNIVERSITY OF PITTSBURGH (US) | 2000-10-17 | — | — | US | disclosed |
| US-6114175-A | AMYLOID-BINDING COMPOUNDS WHICH ARE NON-AZO DERIVATIVES OF CHRYSAMINE G TO DETERMINE DEGREE OF BRAIN DEPOSITS QUANTITATIVELY CHARACTERIZED BY AMYLOIDOSIS; DOWN'S SYNDROME; PREVENT CELL DEGENERATION; RADIOACTIVE IMAGING | UNIVERSITY OF PITTSBURGH (US) | 2000-09-05 | — | — | US | disclosed |
| EP-0977815-A1 | ALKYL, ALKENYL AND ALKYNYL CHRYSAMINE G DERIVATIVES FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND $i(IN VIVO) IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998047969-A1 | ALKYL, ALKENYL AND ALKYNYL CHRYSAMINE G DERIVATIVES FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138374-A1 | Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same | APBA1, S100B, APP | PTPN1 3074/4885PTPN2 3754/4885PTPN6 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.